PropertyValue
?:abstract
  • COVID-19 outbreak has significantly upended solid organ transplant (SOT) practice around the world. Early reports confirmed the heavy burden of COVID-19 in SOT recipients with mortality rates reaching up to 35%. Because most transplant recipients harbored multiple comorbidities known to be associated with a severe course of COVID-19, the true impact of immunosuppression by itself remained an unsolved issue. Transplant societies have initially recommended to postpone non urgent renal transplantations, while trying to maintain life-saving transplant programs, such as heart, lung and liver transplantations. The pandemic thus resulted in an unprecedented and sudden drop of transplant activity worldwide. Moreover, the best treatment strategy in infected patients was challenging. Both reduction of immunosuppression and use of targeted therapies aiming at counteracting SARS-CoV-2 infection were the two faces of the therapeutic armamentarium. Recent controlled studies have better delineated the basis of mitigating and management strategies to improve patients\' outcome. Nevertheless, and given the persistence of circulating virus, evidence-based recommendations in SOT recipients remain unclear. The resumption of transplant activity should be tailored with careful selection of both donors and recipients. Transplant decision should be made on a case-by-case basis after thorough assessment of the risks and benefits.
is ?:annotates of
?:creator
?:doi
  • 10.1097/tp.0000000000003536
?:doi
?:journal
  • Transplantation
?:license
  • unk
?:pmid
?:pmid
  • 33208691.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • Medline
?:title
  • Solid organ transplantation in the era of COVID-19: lessons from the past six months.
?:type
?:year
  • 2020-11-17

Metadata

Anon_0  
expand all